Researched by Belong.Life and published by ASCO
RWED of financial toxicity was reported by the majority of cancer pts receiving Immunotherapy drugs for treatment of their solid tumors. 48% of the pts were aware of possible FTs as a result of their diagnosis and therapy. Only 36% received pre-treatment financial advice by their medical team and in those that received it, the FT incidence reported was reduced from 48% to 30% (absolute Down 37.5%) Physicians should be aware of their pts’s possible risks for FTs and relevant advice should be given prior to the immunotherapy drugs commencement.
